Patient Leaflet Updated 28-Jun-2024 | Galderma (U.K) Ltd
Silkis 3 micrograms per g ointment
Silkis® 3 micrograms/g
calcitriol
OINTMENT
1. What Silkis is and what it is used for
2. What you need to know before you use Silkis
3. How to use Silkis
4. Possible side effects
5. How to store Silkis
6. Contents of the pack and other information
Silkis is used for the topical treatment of mild to moderately severe plaque psoriasis with up to one third of body surface area involvement.
It contains an active ingredient, calcitriol (a vitamin D derivate), which inhibits and normalizes the unrestrained cell growth in psoriasis affected skin.
Talk to your doctor or pharmacist before using Silkis.
There is limited data on the use of Silkis in children. Therefore, use in children should be avoided.
Silkis might interfere with other medicines such as:
Inform your doctor of any other topical treatment you may have used or you are using for your psoriasis lesions, before starting this treatment.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Silkis should not be used if you are breast-feeding.
The treatment does not affect the ability to drive and use machines.
Silkis is an ointment for use on the skin only (cutaneous).
Always use this medicine exactly as your doctor has told you.
Check with your doctor or pharmacist if you are not sure.
Do not swallow this product. If you accidentally do so, seek immediate medical advice.
Regularly follow your treatment, according strictly to your doctor's instructions.
If you feel that the effect of this medicine is too strong or too weak, talk to your doctor or pharmacist.
Do not apply a double dose to make up for forgotten individual doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In case of severe irritation or contact allergy (redness, itching), the treatment should be stopped and the patient should seek medical attention. If contact allergy is confirmed, the treatment should be discontinued.
This medicine may cause some unwanted effects at the site of application:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is Calcitriol (3 micrograms per g).
The other excipients are liquid paraffin, white soft paraffin and alpha-tocopherol.
Silkis is a white, translucent ointment.
This ointment is available on prescription from your doctor in tubes containing 15g, 30g or 100g (not all pack sizes may be marketed).
Marketing Authorisation Holder
PL 10590/0047
Manufacturer
This medicinal product is authorised in the Member States of the EEA under the following names:
Czech Republic: Silkis mast
Germany: SILKIS 3 µg/g Salbe
Spain: SILKIS 3 microgramos/g pomada
Finland: Silkis 3 mikrog/g voide
France: SILKIS 3 microgrammes/g, pommade
Ireland: SILKIS 3 micrograms per g ointment
Italy: SILKIS 3 microgrammi per grammo di unguento
Netherlands: SILKIS, zalf 3 microgram/gram
Norway: Silkis 3 mikrogram per g salve
Portugal: SILKIS 3 microgramas por grama de pomada
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in May 2024.
P27889-4
Evergreen House North, Grafton Place, London, NW1 2DX, UK